Overview

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive Large B-cell Lymphoma Ineligible for R-CHOP

Status:
Not yet recruiting

Trial end date:
2028-09-30

Target enrollment:

Participant gender:

Summary

In the present trial the chemotherapy- light treatment concept R-Pola-Glo will be evaluated that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo) in elderly and/or medical unfit and previously untreated patients with aggressive B-cell lymphoma. The efficacy and feasibility data obtained here will be used for further clinical development of this new chemolight triple combination.

Phase:

Phase 2

Details

Lead Sponsor:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators:

Arbeitsgemeinschaft medikamentoese Tumortherapie
Charite University, Berlin, Germany
Hoffmann-La Roche
Roche Pharma AG
University of Salzburg
Zentrum für Klinische Studien Leipzig

Treatments:

Obinutuzumab
Rituximab